News | Nuclear Imaging | July 06, 2015

Medraysintell Releases 2015 Nuclear Medicine World Market Report

Market value expected to reach $24 billion by 2030, with more than half coming from radiotherapeutics

Medraysintell, nuclear medicine, World Market Report, radiopharmaceuticals

July 6, 2015 - Medraysintell released its updated World Market Report and Directory on Nuclear Medicine, Edition 2015, in late June, providing a description and analysis of the latest developments in nuclear medicine. The 920-page document covers 335 radiopharmaceuticals and radionuclides and 160 companies and institutions active in nuclear medicine.

This new edition, written by experts, features 14 new products evaluated and 24 additional companies assessed. Additionally, it presents an overview of the major manufacturing centers and their capacities for producing radionuclides on a country and regional basis; the status of the molybdenum shortage issue from an economic point of view; and comprehensive comparisons of estimated radionuclide and radiopharmaceuticals pricing observed in key regions of the world.
Several important changes occurred in the past year that will shape the short term of global nuclear medicine. The strong growth of radiotherapeutics represented 8 percent of the total nuclear medicine market in 2014, versus 4 percent in 2013, driven by the success of Xofigo (Bayer). It is expected that radiotherapeutics will represent over 50 percent of the $24 billion nuclear medicine market in 2030.

In radiodiagnostics, the recent developments in gallium-68 make the year 2015 a milestone for the development of this technology, which in the next five years will lead to a completely new positron emission tomography (PET) environment. It seems that the future of radiodiagnostics will entirely be based on technetium-99m for single-photon emission computed tomography (SPECT) and on fluorine-18/gallium-68 for PET.

The conventional pharmaceutical industry has gradually become interested in nuclear medicine with some recent mergers and acquisitions activity: Bayer acquired Algeta; Sun Pharmaceutical Industries acquired Pharmalucence; Otsuka Pharmaceuticals entered into a global licensing and collaboration agreement with NuView Life Sciences; Norgine entered into a partnership with Navidea; and most recently, the pharmaceutical group, Ipsen, acquired OctreoPharm Sciences. In addition, the market saw some major consolidations, with AAA acquiring Atreus and IHS acquiring IBA Molecular North America to merge with their Zevacor.

The global market for nuclear medicine reached $4.3 billion in 2014 compared to $4.1 billion in 2013, exhibiting growth of 5 percent. Without the exchange rate effect against the U.S. dollar, the market would have reached $4.5 billion, and thus would have showed growth of 10 percent versus 2013. Presently, the global nuclear medicine market is rather fragmented, with nearly 70 companies selling radiopharmaceuticals on a regular basis. Three companies control almost half of the world market, while 56 firms share 14 percent of the market. Though nuclear medicine is not a recent science, the past years have witnessed the emergence of new radionuclides, and more than 35 companies are involved in research and development but are not yet selling radiopharmaceuticals.

New opportunities lie ahead in the nuclear medicine landscape. This potential has been identified not only in the radiodiagnostic area, but most notably in therapeutic radiopharmaceuticals, with the first products scheduled to reach the market before the end of 2020. Opportunities exist for larger groups or investors to finance such development, to merge with key partners and/or to acquire companies.

For more information: www.medraysintell.com

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging| August 18, 2017
August 18, 2017 — The American Society of...
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Cardiac Imaging| August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
New PET-CT Scan Improves Detection in Rare Cardiac Condition
News | PET-CT| July 25, 2017
Using a new imaging technique that can diagnose cardiac sarcoidosis much more accurately than traditional tests,...
Sponsored Content | Videos | Business| July 13, 2017
Randall Thompson, M.D., outlines three new CPT codes for FFR-CT, a smart phone-based single-lead ECG system and PET n
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging| July 07, 2017
Blood clots in veins and arteries can lead to heart attack, stroke and pulmonary embolism, which are major causes of...
Sponsored Content | Videos | Clinical Decision Support| June 29, 2017
Rami Doukky, M.D., system chair, Division of Cardiology, professor of medicine, Cook County Health and Hospitals Syst
cardiac nuclear myocardial perfusion imaging (MIP) exam guidelines for women
News | Nuclear Imaging| June 15, 2017
June 15, 2017 — The American Society of Nuclear Cardiology (ASNC) has published an updated consensus statement on evi
Philips Dosewise portal allows X-ray radiation dose tracking for individual patients

An example of radiation dose tracking software is Philips Dosewise portal, which allows X-ray radiation dose tracking for individual patients by modality, body region and exam type.

Feature | Radiation Dose Management| June 13, 2017 | Dominic Siewko
In recent years, radiation dose management awareness has heightened across the healthcare industry to address growing
MIM Software Inc. Announces Updates to MIM Encore
Technology | Remote Viewing Systems| May 31, 2017
MIM Software Inc. recently announced significant updates to its MIM Encore solution for viewing nuclear medicine images...
Overlay Init